{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:10Z","timestamp":1771542190837,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10072-024-07928-4","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T04:38:15Z","timestamp":1734496695000},"page":"2361-2363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Subcutaneous administration of foslevodopa\/foscarbidopa (PRODUODOPA\u00ae) in arm and thigh due to giant epigastric hernia: a case report"],"prefix":"10.1007","volume":"46","author":[{"given":"Sr\u0111ana","family":"Telarovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-236X","authenticated-orcid":false,"given":"Lucija","family":"\u010condi\u0107 Jurjevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"7928_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795\u2013808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7928_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmedgenet-2017-105047","volume":"55","author":"PL Zhang","year":"2018","unstructured":"Zhang PL, Chen Y, Zhang CH, Wang YX, Fernandez-Funez P (2018) Genetics of Parkinson\u2019s disease and related disorders. J Med Genet 55:73\u201380. https:\/\/doi.org\/10.1136\/jmedgenet-2017-105047","journal-title":"J Med Genet"},{"key":"7928_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fneur.2019.00218","volume":"10","author":"N Ball","year":"2019","unstructured":"Ball N, Teo WP, Chandra S, Chapman J (2019) Parkinson\u2019s Disease and the Environment. Front Neurol 10:218. https:\/\/doi.org\/10.3389\/fneur.2019.00218","journal-title":"Front Neurol"},{"issue":"10","key":"7928_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neurol.2017.12.003","volume":"174","author":"A Alexoudi","year":"2018","unstructured":"Alexoudi A, Alexoudi I, Gatzonis S (2018) Parkinson\u2019s disease pathogenesis, evolution and alternative pathways: a review. Rev Neurol (Paris) 174(10):699\u2013704","journal-title":"Rev Neurol (Paris)"},{"issue":"153","key":"7928_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/pharmaceutics15030770","volume":"25","author":"T Pardo-Moreno","year":"2023","unstructured":"Pardo-Moreno T, Garc\u00eda-Morales V, Suleiman-Martos S, Rivas-Dom\u00ednguez A, Mohamed-Mohamed H, Ramos-Rodr\u00edguez JJ, Melguizo-Rodr\u00edguez L, Gonz\u00e1lez-Acedo A (2023) Current treatments and New, tentative therapies for Parkinson\u2019s Disease. Pharmaceutics 25(153):770. https:\/\/doi.org\/10.3390\/pharmaceutics15030770","journal-title":"Pharmaceutics"},{"issue":"1","key":"7928_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","volume":"1","author":"H Murakami","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y (2023) Recent advances in drug therapy for Parkinson\u2019s Disease. Intern Med 1(1):33\u201342. https:\/\/doi.org\/10.2169\/internalmedicine.8940-21","journal-title":"Intern Med"},{"issue":"4","key":"7928_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1212\/WNL.0000000000001184","volume":"84","author":"T Xie","year":"2015","unstructured":"Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, Bernard J, Warnke P, Kang UJ (2015) Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 84(4):415","journal-title":"Neurology"},{"issue":"6","key":"7928_CR8","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC (2023) Continuous Subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12(6):1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"issue":"12","key":"7928_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O\u2019Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"7928_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40263-020-00782-w","volume":"35","author":"S Thakkar","year":"2021","unstructured":"Thakkar S, Fung VSC, Merola A, Rollins M, Soileau MJ, Kov\u00e1cs N (2021) 24-Hour levodopa-carbidopa intestinal gel: clinical experience and practical recommendations. CNS Drugs 35(2):137\u2013149. https:\/\/doi.org\/10.1007\/s40263-020-00782-w","journal-title":"CNS Drugs"},{"issue":"4","key":"7928_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord 30(4):510\u2013516","journal-title":"Mov Disord"},{"key":"7928_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","volume":"37","author":"A Juhasz","year":"2017","unstructured":"Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A et al (2017) Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson\u2019s disease: an open-label study. Parkinsonism Relat Disord 37:79\u201386","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"7928_CR13","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","volume":"266","author":"L Lopiano","year":"2019","unstructured":"Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266(9):2164\u20132176","journal-title":"J Neurol"},{"issue":"3","key":"7928_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1756285616681280","volume":"10","author":"J Virhammar","year":"2017","unstructured":"Virhammar J, Nyholm D (2017) Levodopa-carbidopa enteral suspension in advanced Parkinson\u2019s disease: clinical evidence and experience. Ther Adv Neurol Disord 10(3):171\u2013187","journal-title":"Ther Adv Neurol Disord"},{"key":"7928_CR15","unstructured":"PRODUODOPA\u00ae (2023) (foslevodopa\/foscarbidopa solution for infusion) Summary of Product Characteristics"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07928-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:56:57Z","timestamp":1744804617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07928-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7928"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07928-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from patient included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board approval"}},{"value":"The patient has consented to the submission of the case report to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the proposed manuscript describes original research and is not published or under consideration by another scientific journal. The data\/results of the manuscript are not plagiarized.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}